Hydrochloric Acid

Hydrochloric Acid

SCHEMBL287448

C1=C\CC/C=C\CC/1.C1=C\CC/C=C\CC/1.[Cl-].[Cl-].[Rh+].[Rh+]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9315525-B2 Synthetic route for the preparation of α-amino boronic acid derivatives via substituted alk-1-ynes LEK PHARMACEUTICALS D.D. (SI) 2016-04-19 US claimed
EP-2427419-B1 VINYL ESTER PRODUCTION FROM ACETYLENE AND CARBOXYLIC UTILIZING HOMOGENEOUS CATALYST CELANESE INT CORP (US) 2014-06-18 EP claimed
US-12410153-B2 Compounds, compositions and methods AVALO THERAPEUTICS, INC. (US) 2025-09-09 US disclosed
WO-2024192064-A1 COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A/ PROTEOVANT THERAPEUTICS, INC. (US) 2024-09-19 WO disclosed
US-20230257363-A1 COMPOUNDS, COMPOSITIONS AND METHODS CERECOR INC. 2023-08-17 US disclosed
US-11591314-B2 Process for preparing tetrahydrocarbazole carboxamide compound BRISTOL-MYERS SQUIBB COMPANY (US) 2023-02-28 US disclosed
EP-3237399-B1 COMPOUNDS, COMPOSITIONS AND METHODS AVALO THERAPEUTICS INC (US) 2022-11-30 EP disclosed
US-11479542-B2 Compounds, compositions and methods CERECOR, INC. (US) 2022-10-25 US disclosed
US-11440926-B2 Method for preparing aminopropylsilanes WACKER CHEMIE AG (DE) 2022-09-13 US disclosed
US-20210284666-A1 METHOD FOR PREPARING AMINOPROPYLSILANES WACKER CHEMIE AG (DE) 2021-09-16 US disclosed
US-20210107892-A1 COMPOUNDS, COMPOSITIONS AND METHODS MERCK SHARP & DOHME LLC 2021-04-15 US disclosed
EP-0863145-B1 Sunscreen compositions HOFFMANN LA ROCHE (CH) 2003-10-01 EP disclosed
EP-0785198-B1 Method for the preparation of optically active 3-hydroxyquinuclidine LONZA AG (CH) 2000-07-05 EP disclosed
US-5976512-A SUN SCREENING AGENTS. ROCHE VITAMINS INC. (US) 1999-11-02 US disclosed
EP-0863145-A2 Sunscreen compositions F. HOFFMANN-LA ROCHE AG (CH) 1998-09-09 EP disclosed
US-5744606-A Process for the preparation of optically active 3-quinuclidinol LONZA AG (CH) 1998-04-28 US disclosed
EP-0512415-B1 Process for the enantioselective synthesis of 2(R)-benzyl succanamide derivatives HOECHST AG (DE) 1997-08-06 EP disclosed
EP-0785198-A1 Method for the preparation of optically active 3-hydroxyquinuclidine LONZA AG (CH) 1997-07-23 EP disclosed
US-5321139-A Amination of phenylitaconic anhydride, catalytic reduction of formed amide; renin inhibitor HOECHST AKTIENGESELLSCHAFT (DE) 1994-06-14 US disclosed
EP-0512415-A2 Process for the enantioselective synthesis of 2(R)-benzyl succanamide derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1992-11-11 EP disclosed